280 related articles for article (PubMed ID: 23358409)
1. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
[TBL] [Abstract][Full Text] [Related]
2. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases.
Limouris GS; Chatziioannou A; Kontogeorgakos D; Mourikis D; Lyra M; Dimitriou P; Stavraka A; Gouliamos A; Vlahos L
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1827-37. PubMed ID: 18536916
[TBL] [Abstract][Full Text] [Related]
3. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [
Hebert K; Santoro L; Monnier M; Castan F; Berkane I; Assénat E; Fersing C; Gélibert P; Pouget JP; Bardiès M; Kotzki PO; Deshayes E
J Nucl Med; 2024 Jun; 65(6):923-930. PubMed ID: 38637144
[TBL] [Abstract][Full Text] [Related]
4. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.
Kwekkeboom DJ; Bakker WH; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; de Jong M; Srinivasan A; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):417-22. PubMed ID: 12634971
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
7. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
8. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases.
Limouris GS; Poulantzas V; Trompoukis N; Karfis I; Chondrogiannis S; Triantafyllou N; Gennimata V; Moulopoulou LE; Patsouris E; Nikou G; Michalaki V; Fragulidis G; Paphiti M; McCready RV; Colletti PM; Cook GJ; Rubello D
Clin Nucl Med; 2016 Mar; 41(3):194-200. PubMed ID: 26673241
[TBL] [Abstract][Full Text] [Related]
11. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract][Full Text] [Related]
12. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
13. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases.
Kratochwil C; López-Benítez R; Mier W; Haufe S; Isermann B; Kauczor HU; Choyke PL; Haberkorn U; Giesel FL
Endocr Relat Cancer; 2011 Oct; 18(5):595-602. PubMed ID: 21791571
[TBL] [Abstract][Full Text] [Related]
14. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
Kalshetty A; Ramaswamy A; Ostwal V; Basu S
Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
[TBL] [Abstract][Full Text] [Related]
15. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
16. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
17. [Treatment of Gastroenteropancreatic Neuroendocrine Tumors with 177Lu-DOTA-TATE: Experience of the Portuguese Institute of Oncology in Porto].
Sampaio IL; Luiz HV; Violante LS; Santos AP; Antunes L; Torres I; Sanches C; Azevedo I; Duarte H
Acta Med Port; 2016 Nov; 29(11):726-733. PubMed ID: 28229838
[TBL] [Abstract][Full Text] [Related]
18. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
[TBL] [Abstract][Full Text] [Related]
19. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies.
Vaghaiwalla T; Ruhle B; Memeh K; Angelos P; Kaplan E; Liao CY; Polite B; Keutgen X
Surgery; 2021 Jan; 169(1):162-167. PubMed ID: 32446596
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE.
Gupta SK; Singla S; Thakral P; Bal CS
Clin Nucl Med; 2013 Mar; 38(3):188-94. PubMed ID: 23412597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
